These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 25663295

  • 1. Axitinib plasma pharmacokinetics and ethnic differences.
    Chen Y, Suzuki A, Tortorici MA, Garrett M, LaBadie RR, Umeyama Y, Pithavala YK.
    Invest New Drugs; 2015 Apr; 33(2):521-32. PubMed ID: 25663295
    [Abstract] [Full Text] [Related]

  • 2. Clinical pharmacology of axitinib.
    Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK.
    Clin Pharmacokinet; 2013 Sep; 52(9):713-25. PubMed ID: 23677771
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
    Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP.
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
    [Abstract] [Full Text] [Related]

  • 4. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.
    Pithavala YK, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus KJ.
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):563-70. PubMed ID: 19603168
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
    Garrett M, Taylor T, Mould DR, Amantea MA, Chen Y, Ingrosso A, Pithavala YK.
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1131-1141. PubMed ID: 27783139
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.
    Brennan M, Williams JA, Chen Y, Tortorici M, Pithavala Y, Liu YC.
    Eur J Clin Pharmacol; 2012 May; 68(5):645-55. PubMed ID: 22170007
    [Abstract] [Full Text] [Related]

  • 8. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
    Igarashi R, Inoue T, Fujiyama N, Tsuchiya N, Numakura K, Kagaya H, Saito M, Narita S, Satoh S, Niioka T, Miura M, Habuchi T.
    Med Oncol; 2018 Mar 09; 35(4):51. PubMed ID: 29524031
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.
    Rini BI, Melichar B, Fishman MN, Oya M, Pithavala YK, Chen Y, Bair AH, Grünwald V.
    Ann Oncol; 2015 Jul 09; 26(7):1372-7. PubMed ID: 25701454
    [Abstract] [Full Text] [Related]

  • 12. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
    Chen Y, Rini BI, Motzer RJ, Dutcher JP, Rixe O, Wilding G, Stadler WM, Tarazi J, Garrett M, Pithavala YK.
    Target Oncol; 2016 Apr 09; 11(2):229-34. PubMed ID: 26400730
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.
    Pithavala YK, Tong W, Mount J, Rahavendran SV, Garrett M, Hee B, Selaru P, Sarapa N, Klamerus KJ.
    Invest New Drugs; 2012 Feb 09; 30(1):273-81. PubMed ID: 20740300
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic evaluation of axitinib.
    Patson B, B Cohen R, Olszanski AJ.
    Expert Opin Drug Metab Toxicol; 2012 Feb 09; 8(2):259-70. PubMed ID: 22248343
    [Abstract] [Full Text] [Related]

  • 17. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
    Thiery-Vuillemin A, Orillard E, Mouillet G, Calcagno F, Devillard N, Bouchet S, Royer B.
    Cancer Chemother Pharmacol; 2017 Jun 09; 79(6):1273-1276. PubMed ID: 28451830
    [Abstract] [Full Text] [Related]

  • 18. Axitinib: a review in advanced renal cell carcinoma.
    Keating GM.
    Drugs; 2015 Nov 09; 75(16):1903-13. PubMed ID: 26487541
    [Abstract] [Full Text] [Related]

  • 19. Axitinib for the treatment of advanced renal cell carcinoma.
    Akaza H, Fukuyama T.
    Expert Opin Pharmacother; 2014 Feb 09; 15(2):283-97. PubMed ID: 24328549
    [Abstract] [Full Text] [Related]

  • 20. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
    Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Drug Metab Dispos; 2011 May 09; 39(5):729-35. PubMed ID: 21282407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.